Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Dutch HOVON group, Pieternella J Lugtenburg, Josee M Zijlstra, Jeanette K Doorduijn, Lara H Böhmer, Mels Hoogendoorn, Henriette W Berenschot, Aart Beeker, Nicole C van der Burg-de Graauw, Harry C Schouten, Yavuz M Bilgin, Marie-Jose Kersten, Harry R Koene, Alexandra H E Herbers, Daphne de Jong, Nathalie Hijmering, King H Lam, Dana Chiţu, Rolf E Brouwer, Gustaaf W van Imhoff

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science